• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Bausch & Lomb shareholders approve merger with Warburg Pincus affiliates

Article

Rochester, NY-Bausch & Lomb shareholders have approved the proposed merger of the company with affiliates of Warburg Pincus LLC, according to the company.

Rochester, NY-Bausch & Lomb shareholders have approved the proposed merger of the company with affiliates of Warburg Pincus LLC, according to the company.

“We look forward to promptly completing the transaction,” said Ronald L. Zarrella, chairman and chief executive officer of Bausch & Lomb.

The deal is expected to close early in the fourth quarter. Each outstanding share of Bausch & Lomb common and Class B stock will be canceled and converted into the right to receive $65 in cash, without interest and minus any applicable withholding taxes.

Affiliates of Warburg Pincus are not required to consummate the merger until after expiration of a “marketing period” of 20 business days after the shareholder vote, which was held Sept. 21.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.